StockNews.com Upgrades Applied DNA Sciences (NASDAQ:APDN) to Hold

Applied DNA Sciences (NASDAQ:APDN – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

A number of other analysts also recently issued reports on APDN. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Applied DNA Sciences in a report on Friday, February 10th. Maxim Group cut their target price on Applied DNA Sciences from $6.00 to $3.00 in a research report on Friday, December 16th.

Applied DNA Sciences Stock Up 0.9 %

Shares of NASDAQ APDN opened at $1.08 on Monday. The business has a 50-day moving average of $1.54 and a two-hundred day moving average of $1.70. Applied DNA Sciences has a 1 year low of $0.62 and a 1 year high of $7.35.

Institutional Trading of Applied DNA Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in APDN. Prudential Financial Inc. acquired a new stake in shares of Applied DNA Sciences during the second quarter worth about $34,000. Raymond James & Associates acquired a new position in Applied DNA Sciences in the 4th quarter valued at about $40,000. Virtu Financial LLC acquired a new position in Applied DNA Sciences in the 1st quarter valued at about $49,000. State Street Corp increased its position in Applied DNA Sciences by 53.6% in the 1st quarter. State Street Corp now owns 26,977 shares of the technology company’s stock valued at $58,000 after acquiring an additional 9,416 shares during the period. Finally, Atria Wealth Solutions Inc. acquired a new position in Applied DNA Sciences in the 1st quarter valued at about $67,000. Institutional investors and hedge funds own 15.27% of the company’s stock.

About Applied DNA Sciences

(Get Rating)

Applied DNA Sciences, Inc engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics.